Axon Enterprise, Inc $AXON Shares Sold by Hollencrest Capital Management

Hollencrest Capital Management lowered its position in Axon Enterprise, Inc (NASDAQ:AXON) by 94.0% in the third quarter, Holdings Channel.com reports. The institutional investor owned 150 shares of the biotechnology company’s stock after selling 2,330 shares during the period. Hollencrest Capital Management’s holdings in Axon Enterprise were worth $108,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Westside Investment Management Inc. boosted its stake in Axon Enterprise by 4.8% during the 2nd quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company’s stock worth $225,000 after purchasing an additional 13 shares during the period. CVA Family Office LLC raised its holdings in shares of Axon Enterprise by 26.9% in the second quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 14 shares during the last quarter. Newbridge Financial Services Group Inc. raised its holdings in shares of Axon Enterprise by 2.8% in the second quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock valued at $421,000 after buying an additional 14 shares during the last quarter. Vicus Capital boosted its stake in shares of Axon Enterprise by 3.7% during the third quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock worth $284,000 after buying an additional 14 shares during the period. Finally, Evergreen Capital Management LLC grew its holdings in shares of Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock worth $342,000 after buying an additional 15 shares during the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Stock Down 7.3%

Axon Enterprise stock opened at $509.58 on Friday. The stock’s 50 day moving average price is $579.11 and its 200 day moving average price is $671.49. Axon Enterprise, Inc has a 1-year low of $469.24 and a 1-year high of $885.91. The company has a market cap of $40.21 billion, a PE ratio of 161.26, a price-to-earnings-growth ratio of 17.31 and a beta of 1.41. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.12 and a quick ratio of 2.89.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The business had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. Axon Enterprise’s revenue was up 30.6% compared to the same quarter last year. During the same period last year, the business posted $1.45 EPS. On average, sell-side analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on AXON shares. Royal Bank Of Canada started coverage on Axon Enterprise in a research note on Monday, November 17th. They set an “outperform” rating and a $860.00 price objective for the company. Northcoast Research upgraded Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price target for the company in a research note on Tuesday, January 6th. Wall Street Zen lowered shares of Axon Enterprise from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Morgan Stanley cut their price objective on shares of Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating for the company in a research report on Wednesday, December 17th. Finally, TD Cowen restated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, November 5th. Fourteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $805.71.

Insider Activity

In other Axon Enterprise news, Director Jeri Williams sold 100 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $550.63, for a total transaction of $55,063.00. Following the transaction, the director directly owned 1,316 shares in the company, valued at approximately $724,629.08. This represents a 7.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $619.01, for a total transaction of $6,190,100.00. Following the completion of the transaction, the chief executive officer directly owned 3,100,997 shares of the company’s stock, valued at approximately $1,919,548,152.97. This trade represents a 0.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 60,540 shares of company stock valued at $34,684,738 in the last quarter. Insiders own 4.40% of the company’s stock.

Trending Headlines about Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Robert W. Baird reiterated a Buy rating on AXON, highlighting continued confidence from at least one major sell‑side firm which can provide support if management meets growth targets. Robert W. Baird Remains a Buy on Axon Enterprise (AXON)
• Positive Sentiment: Analysts and contributors (e.g., Seeking Alpha / AppLovin coverage) argue Axon’s AI and software strategy could ignite a new growth flywheel, supporting longer‑term revenue expansion and higher SaaS margins if execution continues. AppLovin: Axon Ignites A New Growth Flywheel
• Neutral Sentiment: Coverage is mixed: a Globe and Mail piece notes analysts are conflicted on AXON, reflecting divergence in views on growth vs. valuation that can increase volatility. Analysts Conflicted on These Industrial Goods Names: RTX (RTX) and Axon Enterprise (AXON)
• Neutral Sentiment: Valuation checkers are mixed: one note argues intrinsic value may sit notably below the current share price — a cautionary datapoint for value‑oriented investors but not a near‑term catalyst on its own. Axon Enterprise, Inc.’s (NASDAQ:AXON) Intrinsic Value Is Potentially 17% Below Its Share Price
• Negative Sentiment: A Yahoo piece highlights potential near‑term EPS pressure as Axon invests to build out AI‑driven software advantages — investors may be penalizing margin and EPS risk in the short run. Is Axon (AXON) Trading Near-Term EPS Pressure for a Deeper AI Software Advantage?
• Negative Sentiment: Market commentary and screening writeups flag that AXON has underperformed peers and recently experienced a sharper intraday dip than the broader market, which can trigger momentum selling. Axon Enterprise Inc. stock underperforms Thursday when compared to competitors
• Negative Sentiment: Zacks and other outlets called out a notable share decline versus the market in recent sessions, reinforcing bearish sentiment and pressuring short‑term technical levels. Axon Enterprise (AXON) Sees a More Significant Dip Than Broader Market
• Negative Sentiment: Short interest rose in January (to ~3.6% of float; ~3.9 days to cover as of mid‑January), a technical headwind that can amplify downside on negative news. (Market data summarized internally.)

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.